Marathon Capital Management Cerus Corp Transaction History

Marathon Capital Management

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$4.41 - $5.69 $11,025 - $14,225	-2,500 Reduced 8.77%	26,000 $138,000
Q2 2020 Aug 14, 2020	SELL	$4.5 - $7.02 $11,250 - $17,550	-2,500 Reduced 8.06%	28,500 $188,000
Q2 2019 Jul 25, 2019	BUY	$4.51 - $6.6 $4,510 - $6,600	1,000 Added 3.33%	31,000 $174,000
Q4 2018 Feb 07, 2019	BUY	$4.89 - $7.16 $2,445 - $3,580	500 Added 1.69%	30,000 $152,000
Q3 2018 Nov 13, 2018	SELL	$6.89 - $7.78 $3,445 - $3,890	-500 Reduced 1.67%	29,500 $212,000
Q2 2018 Aug 07, 2018	SELL	$5.19 - $7.25 $5,190 - $7,250	-1,000 Reduced 3.23%	30,000 $200,000
Q1 2018 May 07, 2018	SELL	$3.56 - $5.74 $10,680 - $17,220	-3,000 Reduced 8.82%	31,000 $169,000
Q4 2017 Feb 13, 2018	SELL	$2.76 - $3.95 $5,520 - $7,900	-2,000 Reduced 5.56%	34,000 $114,000
Q3 2017 Nov 13, 2017	BUY	$2.22 - $2.73 $79,920 - $98,280	36,000	36,000 $98,000

156

147M

84.2K

55.5K

Ticker CERS
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 177,090,000
Market Cap $317M
Description
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...

Get notified when there are updates to the investment portfolio of Marathon Capital Management, based on Form 13F filings with the SEC.

Stay updated on Marathon Capital Management with notifications on news.